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Introduction
Pulmonary hypertension (PH) group 3, according to the 
2003 World Health Organization (WHO) classification of 
PH (1), summarizes PH associated with disorders of the 
respiratory system. Chronic obstructive pulmonary disease 
(COPD), interstitial lung disease (ILD), and obstructive 
sleep apnea (OSA) are most frequently the underlying lung 
diseases in WHO group 3 PH (2). If chronic lung disease 
is accompanied by PH, functional capacity and survival 
will decrease, while complications will increase (2). The 
present article aims to give an overview of the available 
literature describing the outcome and potential therapeutic 
implications for emphysema patients with PH, including 
lung volume reduction surgery (LVRS), although only 
limited data is available for this particular question. 
Epidemiology of PH in lung disease
In contrast to idiopathic pulmonary arterial hypertension 
(PAH) [mean pulmonary artery pressure (mPAP) >25 mmHg], 
the threshold in PH group 3 was set at a resting mPAP 
>20 mmHg in earlier studies (3).
The exact prevalence of PH and cor pulmonale (CP) in 
COPD is unknown, and varies considerably from 20–91% 
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(4-12), which can be explained by variation of PH thresholds 
being used in different studies. In a large study of advanced 
COPD candidates for LVRS or lung transplantation, 
the reported prevalence of PH was just over 50% (7). 
Similar prevalence of 47.6% PH of mPAP ≥25 mmHg 
is reported from the Organ Procurement and Tissue 
Network (OPTN) database of 4,930 COPD patients listed 
for transplant between 1997 and 2006 (13). In contrast to 
this, in the National Emphysema Treatment Trial (NETT) 
PH prevalence was as high as 91% in 120 patients where 
right heart catheterization (RHC) was performed (8). 
Several studies in patients with previous Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) stage IV 
showed that only 3% to 5% of patients present with mPAP 
>35 to 40 mmHg (14-16). The rate of PH progression 
in COPD has been reported to be normally slow with an 
increase in PAP between 1.5–2.8 mmHg/year (17,18). 
Combined pulmonary fibrosis and emphysema (CPFE) 
patients develop more frequently PH, in 30% to 50% of the 
cases with prognostic impact on shorter survival (19-21). 
Pathophysiology
Several mechanisms may be responsible for the pathogenesis 
of PH in the setting of COPD and emphysema: reduction 
of the pulmonary vascular cross-sectional area due to 
parenchymal loss and accompanying alveolar hypoxia, 
hypoxemia and hypercapnia, effects of abnormal pulmonary 
mechanics due to air-trapping and hyperinflation, 
polycythemia (leading to hyperviscosity and hypervolemia), 
and inflammation-induced vascular remodeling related to 
smoking (7,16). Vascular remodeling is further triggered 
by chronic hypoxic pulmonary vasoconstriction leading to 
intimal medial hypertrophy of small pulmonary arteries (22) 
(Figure 1). 
Right and left ventricular (LV) function in CP 
With rising  pulmonary vascular resistance (PVR), the right 
ventricle (RV) slowly becomes hypertrophic and dilated. 
Severe emphysema is always associated with hyperinflation, 
and the low elastic recoil of the lungs compresses the two 
ventricles into each other (23), hindering the RV to dilate 
and increase end-diastolic volume and therefore resulting in 
lower cardiac output (CO) due to decreased RV preload. LV 
function depends on RV function and is therefore altered 
too, because changes in RV output must invariably alter LV 
preload, as the two ventricles are serially linked through 
the pulmonary vasculature. Furthermore, LV preload 
can also be directly influenced by changes in RV end-
diastolic volume (RVEDV) by the mechanism of ventricular 
interdependence in a common pericardial pocket. 
At this point, LVRS with a decrease of hyperinflation 
and therefore a decrease in intrathoracic pressure may help 
to increase cardiac function (24), which will be further 
discussed in the following paragraphs. 
Clinical relevance and effect of PH on prognosis 
In COPD an accelerated further increase of mPAP is 
Figure 1 Vascular remodeling in an emphysema patient with PH (A, hematoxylin eosin staining; B, Elastica van Gieson staining), showing 
narrowing of the arterial lumen due to eccentric intimal hyperplasia and fibrosis. Courtesy of Dr. B. Vrugt, Institute of Pathology, University 
Hospital Zurich Switzerland. PH, pulmonary hypertension.
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characteristic even under modest exercise conditions, 
suggesting deficits of lung vascular distension and/or vessel 
recruitment ability (25). In patients with severe COPD, 
PAP may double to its resting value (26), this means that 
for those patients even daily activities such as walking or 
climbing stairs can lead to transient PH. Furthermore, it 
has been shown that PAP can rise by nocturnal desaturation 
in COPD patients, but its role in the pathogenesis of PH 
and CP is not clear (27,28).
Patients with increased PAP also have increased 
morbidity and adverse events, which has for example 
been demonstrated (29) to result in a doubling of the 
hospitalization rate in patients with COPD with PH in 
comparison to those without PH. Furthermore, PAP and 
pCO2 were the only two factors independently predicting 
hospitalization. Another predictor of hospitalization due to 
acute COPD exacerbation seems to be larger PA diameter 
measured in computed tomography (CT) scan (30).
The presence of PH in COPD patients has also an 
impact on overall prognosis as it has been shown to be 
of a strong predictor of mortality (Figure 2). Even if only 
moderate; an inverse correlation between mPAP and/
or PVR values and survival has been reported (4,15,31). 
For COPD patients PH >25 mmHg (Figure 3), the 
5-year survival rate is relevantly decreased and it has 
been demonstrated that pulmonary hemodynamics have 
a bigger prognostic impact on survival than FEV1 or the 
degree of hypoxemia or hypercapnia (31). For COPD 
patients with severe PH >40 mmHg, 5-year survival is 
only about 15% (14,32). 
Diagnostic assessment
The routine assessment of PAP in COPD patients is not 
stated in the most recent GOLD recommendation for 
diagnosis and initial assessment by the GOLD guidelines (33). 
Clinical features
Unfortunately, the clinical features are not sensitive and 
specific: the classical signs of PH and CP like loud pulmonic 
valve closure (P2), third heart sound (S3) gallop, systolic 
murmur of tricuspid regurgitation are reduced due to 
hyperinflation (34).
Brain natriuretic peptide (BNP)
In severe cases of PH due to COPD or diffuse parenchymal 
lung diseases levels of BNP or the N-terminal prohormone 
of BNP in plasma are elevated. In moderate PH BNP 
lacks sensitivity as it can also be increased due to left 
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Figure 2 Effect of mPAP on survival in 176 consecutive patients 
with various pulmonary diseases, most of which were COPD (n=45) 
and ILD (n=55). mPAP, mean pulmonary artery pressure; COPD, 
chronic obstructive pulmonary disease; ILD, interstitial lung 
disease. From Klinger, 2016 (2).
Figure 3 Effect of mPAP on survival in patients with COPD 
according to severity of mPAP increase. Note the marked negative 
effect on survival as PH becomes more severe (2). mPAP, mean 
pulmonary artery pressure; COPD, chronic obstructive pulmonary 
disease; PH, pulmonary hypertension. From Klinger, 2016 (2).
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heart abnormalities (35). However, in a mixed diffuse 
parenchymal lung diseases population BNP levels showed a 
strong predictive value for mortality (36).
Chest radiography
PH can be diagnosed with 98% sensitivity, if the diameter 
of the right descending pulmonary artery (PA) is increased 
(>16 mm, postero-anterior projection) together with an 
increased diameter of the left descending PA (>18 mm, left 
lateral projection) (37) (Figure 4).
ECG
The sensitivity to detect right ventricular hypertrophy is 
very low. Poor prognosis is reported if S1S2S3 or right 
atrial overload pattern, i.e., P wave axis of +90° or more, are 
present (38).
Echocardiography
As non-invasive tool for the diagnosis of PH in COPD 
Doppler transthoracic echocardiography is the first 
diagnostic test used. In patients with lung diseases, a 
positive predictive value of 32% (in comparison to 68% 
RHC) and a negative predictive value of 93% (compared to 
67% for RHC) are stated (39,40). Optimal visualization of 
the heart for tricuspid regurgitation by Doppler is hindered 
by hyperinflation and therefore assessment of systolic PAP 
(sPAP) was achieved only in 38% of patients, as reported 
for 253 COPD candidates for lung transplantation (41). In 
cases of important hyperinflation (residual volume >150%), 
the measurement of sPAP assessment was less feasible. 
This depends obviously significantly on the examiner’s 
experience. Echocardiographically estimated sPAP showed 
a sensitivity of 76%, a specificity of 65%, a negative 
predictive value of 93% and a positive predictive value of 
32% for the diagnosis of PH (39). If sPAP assessment was 
impossible, the values for RV abnormal morphology were 
84%, 56%, 96%, and 22% respectively. For the exclusion 
of PH the negative predictive value is sufficient, but for the 
diagnosis of PH RHC is required.
CT scan
Typical CT systemic vascular characteristics (Figure 5) are: 
enlargement of central pulmonary vessels, enlargement and 
hypertrophy of RV, pericardial effusion.
Magnetic resonance imaging (MRI)
Contrast MRI reflects very well the RV structure and 
function. The thickness of the RV wall and the mean PAP 
show a high correlation (r=0.9) (42). One study measured 
PA cross-sectional area using MRI to assess if pulmonary 
hyperinflation correlates with PA cross-sectional area in 
Figure 4 Chest radiography AP and lateral, courtesy of Prof. T. Frauenfelder, Institute of Diagnostic Radiology, University Hospital Zurich, 
Switzerland. AP, anteroposterior.
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COPD (43) and it has been demonstrated that increased 
residual volume was associated with a larger PA in COPD.
RHC 
RHC is still the gold standard for precise PAP measurement. 
With RHC it is also possible to measure the transpulmonary 
gradient and CO, and to calculate PVR as well as its 
reversibility by drugs and oxygen. Exercise induced PH 
can also be investigated. Severe PH (mPAP >40 mmHg) 
is rarely seen in COPD and in these cases an additional 
explanation for PH should be investigated, e.g., left heart 
disease, chronic thromboembolic disease or idiopathic. 
Cardiopulmonary exercise testing (CPET)
Exercise testing is an excellent tool to differentiate between 
an exhausted breathing reserve caused by airflow limitation 
and an exhausted circulatory reserve caused by PH (44).
Treatment
Even though PAP has a strong negative impact on survival 
in most lung diseases, findings from a limited number of 
studies suggest that successful treatment of PH does not 
necessarily improve patients’ outcome. Before starting a PH 
treatment for patients with chronic lung disease, it has to be 
considered, whether improving pulmonary hemodynamics 
in chronic lung disease has an impact on patients outcome, 
because in most of these patients symptoms are rather 
caused by limitations in ventilation than by CO, unlike 
those with idiopathic PAH (2). Management of the 
underlying lung disease is the primary goal of treatment, as 
there is currently no medication proven to efficiently treat 
PH associated with chronic lung disease. In cases of severe 
PH, patients should be referred to experienced PAH centres 
and enrollment in clinical trials should be considered. 
Over the past 2 decades, a large number of drugs have 
been approved for WHO group 1 PAH, leading to the 
temptation to also use these medications in the treatment of 
PH associated with chronic lung disease (2).
Therapy of CP 
Treatments include α1-antagonists, β2-agonists, angiotensin 
converting enzyme inhibitors, calcium channel blockers, 
nitrates, and theophylline (45). The majority of these 
drugs influence PH only modestly, as on the one hand 
they increase CO and reduce PVR, but on the other hand 
also lead to systemic hypotension and deterioration of 
ventilation-perfusion mismatch. Whether these alternative 
treatments lead to a benefit of survival has not yet been 
shown for any of them (45).
Oxygen
In the 1970s, the efficacy of supplemental oxygen to reduce 
PAP in COPD was first studied. The effects of long-term 
oxygen therapy (LTO2) on pulmonary hemodynamics, 
patient function, and survival was assessed in two large 
multicenter studies. Although it has been demonstrated that 
mortality was relevantly influenced by the oxygen therapy, 
Figure 5 CT systemic vascular characteristics. a, enlargement of central pulmonary vessels; b, enlargement and hypertrophy of RV. (Courtesy 
Prof. T. Frauenfelder). RV, right ventricle.
S2768
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2018;10(Suppl 23):S2763-S2774jtd.amegroups.com
Opitz and Ulrich. PH in COPD and emphysema
increased survival was not correlated with changes in 
pulmonary hemodynamics (17). This was further confirmed 
by the Nocturnal Oxygen Therapy Trial [randomized to 
overnight (average 12 h/d) or continuous (average 17.7 h/d) 
LTO2 (46)] which showed nearly double mortalities in 
nocturnal vs the continuous oxygen therapy group, but 
showed no differences in mPAP and PVR between the 
group of continuous oxygen compared to the group who 
used oxygen only at night. However, oxygen is still vital in 
the treatment for PH in COPD patients.
Pulmonary vasodilators
The use of vasodilatators is complicated by the negative 
effect on oxygenation by inhibiting the ventilation perfusion 
mechanism. However, small series in well selected patients 
showed a benefit (47,48). 
Nitrite oxide was tested in one long-term study in 40 
patients who were additionally under LTO2 (49). Although 
significant improvement of PAP, PVR and CO was 
demonstrated, technological and toxicological problems 
connected to long-term use of inhaled NO still need to be 
resolved. 
Inhaled prostanoids can acutely lead to reduction of 
mPAP and PVR without negative impact on gas exchange 
in PH-COPD (50), but long-term effects have not been 
studied so far. 
Controversial data exist about the effect of endothelin 
receptor antagonists in PH-COPD. Bosentan was assessed 
in a small randomized controlled trial in COPD patients 
with no or only mild PH assessed by echocardiography. 
While gas exchange was even deteriorated, peak oxygen 
uptake, exercise capacity, and quality of life were also 
not improved (51). Valerio et al. reported, that Bosentan 
treatment can improve exercise capacity in PH-COPD 
patients (52). 
Shor t - te rm app l i ca t ion  o f  phosphodie s te ra se 
inhibitor sildenafil was tested in PH-COPD and better 
hemodynamics, but at the same time worsened gas exchange 
was documented (53). This is further confirmed by a small 
randomized controlled trial in patients with severe PH-
COPD upon long-term use of sildenafil where a reduction 
in PAP and an increase in 6-minute walking distance, was 
observed (54). Taken together, there is no evidence that 
patients with COPD without severe PH have a long-term 
benefit from sildenafil treatment.
PH-COPD patients on riociguat medication showed 
improved pulmonary hemodynamics in the absence of 
major gas exchange deterioration (55). Further studies are 
needed to explore this indication for riociguat. 
LVRS
LVRS significantly improves lung function, gas exchange, 
exercise capacity, quality of life and even survival for 
emphysema patients when compared to medical treatment 
(56,57). Experienced centers with careful patient selection, 
can reach a 90 days-postoperative mortality rate nearing 
zero (58,59). PH is still an exclusion criteria for LVRS 
for emphysema patients (60). This was based on the idea 
that resection of lung tissue and therefore reduction of the 
vascular bed would favor PH. However, PVR and therefore 
PH should improve due to the by LVRS achieved reduction 
of hyperinflation and air-trapping. It is not clear though 
if the change of PH after LVRS is caused by reduction in 
hyperinflation only or rather by improved arterial oxygen 
tension. In two case series with endoscopic lung volume 
reduction with valves, it has been shown that clinical and 
hemodynamic parameters (PH and RV function) improved 
without increasing morbidity and mortality of the procedure 
(61,62). Limited data on the influence of LVRS on cardiac 
function and hemodynamics exist and are controversial. 
Haniuda et al. (63) compared the results of seven patients 
6 months before and after LVRS at rest and during exercise 
with the results of eight pulmonary lobectomy patients: after 
lobectomy, sPAP was strongly increased during exercise, 
while sPAP at rest or during exercise was not influenced by 
LVRS. In none of the groups cardiac index was influenced, 
neither at rest nor during exercise. In the LVRS group the 
elevation of wedge pressure during exercise even ameliorated 
(P<0.01). This was further confirmed by Criner et al. (64), 
in a cardiovascular subanalysis of three out of seventeen 
centers for the NETT: after LVRS PAP did not increase 
in comparison with medical therapy. The same results 
are reported from Kubo and colleagues (65): PAP at rest 
or during exercise is unaffected six months after bilateral 
LVRS. A slight, but non-significant decrease in exercising 
mPAP was shown in a small study including 9 LVRS 
patients; mPAP at rest was unaffected (66). In contrast to 
this, another small study (67) reported an increase in mean 
PAP in 9 subjects from 26.5 to 31.8 mmHg 3 months after 
surgery, and in 3 patients PAP even rose to 60 mmHg or 
greater. In another prospective, longitudinal study, nine 
emphysema patients with an average age of 64.4 yr. treated 
with LVRS experienced a significant rise of FEV1 from 0.64 
preoperatively to 0.99 L postoperatively. In the same study 
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PAP rose to 47.9±12.4 mmHg after surgery, but the change 
was not statistically significant (67). 
In our own cohort, we retrospectively assessed the 
effect on PH in 119 LVRS patients (68), and we could 
demonstrate even significant improvement of PH in 
patients with heterogeneous emphysema. In patients with 
PH, median sPAP decreased from 41 mmHg [interquartile 
range (IQR) 39–47 to 37 mmHg (IQR) 36–38, P=0.04]. 
FEV1 improved in these patients three months after surgery 
from median 27% predicted (IQR 23–34) to 33% (IQR 
28–40, P=0.007) (Table 1). These inverse changes of PAP 
levels with FEV1 in a subset of patients treated with LVRS 
have also been documented by other groups (7,8).
In terms on the effect of LVRS on RV function, the 
results are equally controversial: whereas some groups 
showed (65,69) that cardiac index, both at rest and during 
exercise, increased 6 months after LVRS, Sciurba et al. (23) 
reported that LVRS significantly increased RV systolic 
function (Figure 6); other groups could not confirm these 
findings (63,66,67). The improvement in RV function 
may be explained by several facts: due to the reduction of 
hyperinflation, a decrease of the intrathoracic pressure might 
cause an improved RV filling—and therefore improved RV 
preload—reflected in increased RVEDVs after LVRS as 
described by Mineo et al. (69). Another explanation is that 
throughout the reduction of hyperinflation, pressure on the 
vessels is decreased or—by improvement of elastic recoil—
induced tethering of extra-alveolar vessels, a reduction of 
PVR by capillary recruitment is obtained by LVRS (6,70). 
This holds particularly true during exercise, as these large 
intrathoracic pressure swings are a well-known mechanism 
for emphysematous patients to overcome the loss of 
lung elastic recoil. In the study by Oswald-Mammosser, 
a significant decrease of the respiratory swings of the 
pulmonary diastolic pressure at rest and during exercise was 
observed after surgery, alongside with a good correlation 
between the change in mean PAP after LVRS at rest, as 
well as during exercise, and the change in the resting PA 
Table 1 Lung function of patients with sPAP < or > 35 mmHg pre- and post LVRS
Variables Median preoperative (IQR) Median postoperative (IQR) ∆ from baseline (%) P value
sPAP <35 mmHg (n=20)
FEV1 (% predicted) 24 [20–30] 29 [23–33] 21 0.020
FEV1 (mL) 700 [515–948] 800 [590–990] 14 0.003
TLC (% predicted) 122 [112–148] 119 [107–137] −2 0.001
TLC (mL) 7,620 [6,732–9,670] 7,060 [5,500–9,630] −7 0.001
RV (% predicted) 231 [180–275] 208 [165–246] −10 0.001
RV (mL) 4,785 [4,235–6,443] 4,415 [3,552–5,570] −8 0.001
RV/TLC (%) 67 [62–73] 62 [55–66] −2 0.001
DLCO (% predicted) 31 [22–37] 25 [16–39] −7 0.394
sPAP >35 mmHg (n=10)
FEV1 (% predicted) 27 [23–34] 33 [28–40] 22 0.007
FEV1 (mL) 675 [635–785] 805 [760–1,020] 19 0.007
TLC (% predicted) 129 [126–163] 125 [106–143] −3 0.086
TLC (mL) 7,380 [6,620–9,667] 6,435 [6,115–7,457] −13 0.047
RV (% predicted) 266 [224–310] 227 [187–244] −15 0.012
RV (mL) 5,710 [4,885–7,915] 4,605 [3,820–5,280] −19 0.018
RV/TLC (%) 76 [73–79] 66 [59–71] −13 0.013
DLCO (% predicted) 32 [21–38] 30 [15–41] −6 0.686
DLCO, carbon monoxide diffusion capacity; sPAP, systolic pulmonary artery pressure; FEV1, forced expiratory volume in 1 s; IQR, 
interquartile range; RV, residual volume; TLC, total lung capacity.
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diastolic pressure (r=0.73, P<0.03 and r=0.80, P<0.02, 
respectively) (66). This is further supported by other studies 
(71-73), showing that diffusion capacity even increased after 
LVRS. This suggests that the alveolo-capillary gas exchange 
surface is not negatively influenced; maybe because damage 
to the vascular bed was only minimal as a result of a well-
targeted resection zone, or possibly that more capillaries 
are recruited after LVRS. Several studies demonstrated that 
LVRS did not significantly change PaO2 or PaCO2 at rest 
or during exercise (74). 
In a prospective, open, controlled study of LVRS 
patients with severe emphysema (10 patients) compared to 
cancer lobectomy serving as control subjects (10 patients), 
the effect on LV function was assessed by transesophageal 
echocardiography, and hemodynamics were assessed 
by RHC before and after surgery. Preoperative LV 
function was impaired in LVRS patients [lower CI, 
stroke volume index (SVI)] in comparison to patients 
undergoing lobectomy for lung carcinoma, and improved 
postoperatively after LVRS as reflected by an increase in 
LV end-diastolic morphology, and therefore improved LV 
function. The pressure reduced LV function in the LVRS 
groups might be explained again by dynamic hyperinflation 
decreasing the intrathoracic blood volume, which further 
generates an intrinsic positive end-expiratory pressure 
(PEEP) (75-78). Indeed, it has been demonstrated that 
patients with severe emphysema have intrinsic PEEP levels 
between 5–7.5 cmH2O (76,77), which has been further 
correlated to impairment of RV and LV end-diastolic 
dimensions in assessments of patients and volunteers 
(79-85). Taken together, these results strongly support the 
idea that LVRS in patients with severe emphysema might 
increase both RV and LV function after surgery. 
Summary and conclusions
 Prevalence of PH and CP in COPD patients ranges 
from 20–91%, but is mostly only moderate with mPAP 
usually not exceeding 30 mmHg.
 Morbidity and mortality in chronic lung disease is 
strongly affected by the presence of even moderate PH.
 PH in chronic lung disease is caused by multiple factors 
including reduction of the pulmonary vascular cross-
sectional area, hypoxia, effects of abnormal pulmonary 
mechanics due to hyperinflation, but also vascular 
remodeling processes.
 Management of the underlying lung disease is the 
primary goal of treatment, as there is currently no 
medication proven to efficiently treat PH associated 
with chronic lung disease. 
 In cases of severe PH, patients should be referred to 
experienced PAH centres and enrollment in clinical 
trials should be considered. 
 Based on the present literature lacking prospective or 
randomized data, LVRS has in most series no adverse 
effect on pulmonary hemodynamics. The decrease 
of PVR resulting from better pulmonary mechanics 
with reduction of hyperinflation, and improved elastic 
recoil might compensate for the anatomic reduction 
of the vascular bed. If resection areas are well targeted, 
this effect may be even positive for pulmonary 
hemodynamics, which needs to be demonstrated in 
further prospective trials. 
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Figure 6 Mean (±SE) lung volume as a function of mean (±SE) 
transpulmonary pressure before (open circle) and after (solid Circle) 
lung-reduction surgery in 20 patients with diffuse emphysema. 
Note the shift to the right and downward in maximal elastic-recoil 
pressure and total lung capacity. Lung volume is represented as a 
percentage of the )total lung capacity. The curve represents the 
mean response in normal subjects (22). SE, standard error. 
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